



Martina Schneider

Kontakt

Martina Schneider

Publikationen (4)

Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. *J Clin Oncol* 2023; 41:5131-5139.

Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. *Lung Cancer* 2022; 172:154-159.

Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitter M, Wannesson L, Jörgen M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. *Cancer Immunol Immunother* 2020

Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. *Clin Lung Cancer* 2016

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch